{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"191","upperLimit":"302","value":"232"},{"groupId":"OG001","lowerLimit":"217","upperLimit":"300","value":"245"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"144"},{"groupId":"OG001","value":"142"}],"units":"Participants"}],"description":"Progression-free survival was defined as the time interval between randomization and the first documented sign of disease progression (including relapse from complete response \\[CR\\]) by the European Bone Marrow Transplant (EBMT) criteria or death, whichever occurred first. Relapse from CR requires at least 1 of the following: Reappearance of serum or urinary M-protein on immunofixation or routine electrophoresis, confirmed by at least 1 further investigation and excluding oligoclonal immune reconstitution; Greater than or equal to (\\>=) 5 percent (%) plasma cells either in a bone marrow aspirate or on trephine bone biopsy; Development of new lytic bone lesions or soft tissue plasmacytomas or definite increase in the size of residual bone lesions (development of a compression fracture does not exclude continued response and may not indicate progression); Development of hypercalcemia not attributable to any other cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bortezomib 1.3 mg/m\\^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10- day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period along with matching placebo administered as intravenous infusion once every 2 weeks during 42-day treatment phase. Bortezomib 1.3 mg/m\\^2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13- day rest period (cycle Days 23 to 35) along with matching placebo once every 2 weeks during 35-day Maintenance Phase. Dexamethasone tablet will be administered at first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 milligram per day (mg/day) will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles.","id":"OG000","title":"Part 2 - Bortezomib + Placebo"},{"description":"Bortezomib 1.3 mg/m\\^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10- day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period along with Siltuximab administered as intravenous infusion once every 2 weeks during 42-day treatment phase. Bortezomib 1.3 mg/m\\^2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) along with Siltuximab administered as intravenous infusion once every 2 weeks for 35-day Maintenance Phase. Dexamethasone tablet will be administered at first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles.","id":"OG001","title":"Part 2 - Bortezomib + Siltuximab"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat (ITT) population included all participants randomized in Part 2. Participants were analyzed as per initial randomization.","reportingStatus":"POSTED","timeFrame":"Randomization until disease progression or death, which ever occured first (maximum up to 5 years)","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"days"}